Author/Authors :
Naderi, Majid Genetics of Non-Communicable Disease Research Center - Zahedan University of Medical Sciences, Zahedan, Iran , Malek, Fatemeh Pedia-tric Congenital Hematologic Disorders Research Center - Research Institute for Children’s Health - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Miri Aliabad, Ghasem Department of Pediatrics - Zahedan University of Medical Sciences, Zahedan, Iran , Behnampoor, Mahammad Department of Pediatrics - Zahedan University of Medical Sciences, Zahedan, Iran , de Sanctis, Vincenzo Pediatric and Adolescent Outpatient Clinic - Quisisana Hospital, Ferrara, Italy , Karimi, Mehran Hematology Research Center - Shiraz University of Medical Sciences, Shiraz, Iran
Abstract :
This article reviews the current knowledges of congenital bleeding disorders (CBD) amid the COVID-19 pandemic. It appears that CBD is not associated with higher risk of getting COVID-19 and so the prevalence of COVID-19 among them seems not higher compared to the general population. In absence of specific therapeutic recommendations, it is essential to make a correct assessment of the risk of haem-orrhage/thrombosis. Based on expert opinion, strategies for outpatient management include adherence to prescribed regimens, telemedicine, and communication about COVID-19 in patients with CBD. More data should be also collected to better characterize the impact of COVID-19 on patients with CBD. The current findings encourage further studies to determine the prevalence of SARS-CoV2 infection in CBD patients to understand more fully the burden of this novel pathogen and to develop adequate preventive measures against this infection. (www.actabiomedica.it)
Keywords :
COVID-19 , congenital bleeding disorders , treatment , surveillance
